Accelerate to Discover

Back to filter

Related topics

Early fetal sex determination using micro-volume of maternal plasma

BJS Biotechnologies

Jun 16, 2018

 A qPCR-based assay, SneakPeek Early Gender Test (Gateway Genomics) has been developed to determine fetal sex as early...

3R Compliant drug development studies

Bruker Biospin

Jun 8, 2018

In preclinical imaging, magnetic resonance imaging (MRI) can be an attractive alternative to researchers who have...

Kinase study of cytotoxicity voted paper of the year.

Acea Biosciences

Jun 6, 2018

Society of Toxicology voted a xCELLigence based paper the Paper of the Year. The study of cytotoxicity was done using...

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Acea Biosciences

Jun 4, 2018

Search for dual action drugs against both HIV and Tuberculosis has lead to the creation of heterodimeric compounds with...

Jun 18, 2018

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Yokogawa

Jun 1, 2018

Lung cancer is a highly malignant tumor, and targeted delivery of anti‐cancer drugs to deep lung tumor tissue remains a...

Method to quantify local force distribution within biomolecular systems

LUMICKS

May 24, 2018

The journal Nano Letters has recently published the article “Quantifying Local Molecular Tension Using Intercalated DNA...

Bionano fall user workshop

BioNano Genomics

May 23, 2018

We are happy to announce the Bionano Genomics’ 2018 user workshop taking place in San Diego on October 15-16,...

Jun 18, 2018

Registering FDG/PET mouse and AMYViD/PET-CT rat studies to brain VOI atlases

Bruker Biospin

May 22, 2018

Preclinical NeuroPET is employed widely in studies of stroke, ischemia, addiction and eurodegenerative diseases. In...

Show all topics (10)

Human solid tumor cytomics: revealing novel melanoma and immune cell subsets

Jun 27, 2016

We know that cellular heterogeneity in the tumor microenvironment complicates the diagnosis and treatment of cancer. Tumors are complex, dynamic systems composed of diverse cell types in various functional states, including cancer cells and infiltrating immune cells. Resolving this cellular heterogeneity requires a single-cell approach, as analyses on bulk cell preparations mask the heterogeneity and complexity of the biological system and may lead researchers down the wrong path.
Cutting-edge single-cell analysis tools for exploring the genomic, transcriptomic and proteomic states of both tumor and related immune cells are enabling researchers to understand system heterogeneity, identify cells with previously unrecognized phenotypes and elucidate important therapeutic mechanisms.
Tumors are composed of diverse cell types, including cancer cells that can differentially evade therapy and immune cells that may aid or impede treatment. This webinar highlights high-content single-cell approaches developed by the Irish lab for systems immunology and cancer biology studies of human solid tumors, including melanoma and brain cancer. It also discusses technical and biological quality controls, computational analysis and the strengths of combining single-cell approaches, such as mass cytometry, phospho-flow, imaging, transcript profiling and sequencing. These cytomic approaches are especially powerful for dissecting cellular mechanisms of treatment response, monitoring key biomarkers and precise targeting of clinically relevant cell subsets.
Click to watch the video: https://www.fluidigm.com/media#075976ec-8d88-4516-b438-2909ad8f01b0

 

Application
Product news

Related technologies: Automated Single-cell Genomics

Brand profile

Fluidigm

Fluidigm is a Molecular and Single Cell Biology company that creates microfluidic-based chips and instrumentation for Life-Science research.

Related products

A new standard for high-throughput real-time PCR, end-point PCR and digital PCR

show detail

The first automated solution for single-cell genomics, now capable of even more

show detail

Time-of-Flight Mass Cytometer for highly multi-parametric single cell data

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey